Drug
Apabetalone clinical trials
Also written RVX000222 and RVX-208.
- studies test it
- 13
- open now
- 2
- in phase 3
- 3
- first study started
- 2008
Keep track of what changes. Save the apabetalone studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
13 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2019 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 3
- Phase 2
- 11
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 2
Resverlogix Corp (11) · Steeve Provencher (1) · Laval University (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses apabetalone is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Study of Apabetalone in Subjects With Long -COVIDRecruitingPhase 2/3Resverlogix CorpNCT06590324Written as Apabetalone
- A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With HemodialysisNot yet recruitingPhase 1/2Resverlogix CorpNCT03160430Written as apabetalone
- An Open-Label Study of Apabetalone in Covid InfectionTerminatedPhase 2/3Resverlogix CorpNCT04894266Written as Apabetalone
- Safety and Effect of Oral RVX000222 in Subjects With Fabry DiseaseWithdrawnPhase 1/2Resverlogix CorpNCT03228940Written as RVX000222
- Apabetalone for Pulmonary Arterial HypertensionStatus unknownPhase 2Laval UniversityNCT04915300Written as Apabetalone
- Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery DiseaseCompletedPhase 2Resverlogix CorpNCT01058018Written as RVX000222
- Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL CholesterolCompletedPhase 1/2Resverlogix CorpNCT00768274Written as RVX000222
- Apabetalone for Pulmonary Arterial Hypertension: a Pilot StudyCompletedEarly Phase 1Steeve ProvencherNCT03655704Written as Apabetalone
- Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CADCompletedPhase 3Resverlogix CorpNCT02586155Written as Apabetalone
- Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in DyslipidemiaTerminatedPhase 2Resverlogix CorpNCT01863225Written as RVX000222
- The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetesCompletedPhase 2Resverlogix CorpNCT01728467Written as RVX000222
- ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression EvaluationCompletedPhase 2Resverlogix CorpNCT01067820Written as RVX000222
- The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I StimulationCompletedPhase 2Resverlogix CorpNCT01423188Written as RVX000222
Codes
What other systems call apabetalone · ClinicalTrials.gg INT001005
- MeSH (NLM) C000628794apabetaloneOne source NLM
- UNII (FDA) 8R4A7GDZ1DAPABETALONEConfirmed FDA, NLM, Wikidata
- Wikidata Q21099554apabetaloneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171748ApabetaloneOne source FDA
- DrugBank DB12000One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000628794 | apabetalone | One source NLM |
| UNII (FDA) | 8R4A7GDZ1D | APABETALONE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q21099554 | apabetalone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171748 | Apabetalone | One source FDA |
| DrugBank | DB12000 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.